This is a summary of an article published in The New England Journal of Medicine about the EPITOPE clinical study, which tested a skin patch called ViaskinTM Peanut 250 μg (micrograms) as a treatment option for peanut allergy in children aged 1 through 3 years. The patch is a form of epicutaneous immunotherapy (EPIT), which is a new approach to allergen immunotherapythat delivers a small amount of peanut protein to the immune system through the skinThis Plain Language Summary of Publication article from Immunotherapy summarises an article on a study called EPITOPE. Epicutaneous immunotherapy for peanut allergy is a new approach where a small amount of peanut protein is delivered through the skin. The EPITOPE study tested a skin patch called ViaskinTM Peanut 250 μg (micrograms) as a treatment option for peanut allergy in toddlers ( aged 1 through 3 years).

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Phase 3 Trial of Epicutaneous Immunotherapy With Viaskin Peanut in Young Toddlers’ and was published in The New England Journal of Medicine. 

Visit The New England Journal of Medicine using the link to read the original article.